Prevention and treatment of coronary heart disease: who benefits?
1State University of New York-Downstate Medical Center, Brooklyn, New York, USA.
Insights
Coronary heart disease (CHD) remains a leading cause of death, yet screening and treatment strategies are debated. Ongoing trials aim to clarify optimal prevention and treatment for diverse patient groups.
Area of Science:
- Cardiology
- Preventive Medicine
- Public Health
Background:
- Coronary heart disease (CHD) is a major cause of death in the US, despite advances in understanding atherosclerosis, risk factors, and lipid-lowering therapies.
- The effectiveness of statins has improved CHD management, but controversies persist regarding screening and treatment protocols for primary and secondary prevention.
- Specific populations, including postmenopausal women, the elderly, and young adults, present unique challenges in diagnosis and treatment for CHD prevention.
Purpose of the Study:
- To review current controversies in coronary heart disease (CHD) screening and treatment.
- To highlight the role of statins in secondary prevention and discuss primary prevention challenges.
- To identify patient groups that are undertreated or underdiagnosed for CHD.
Main Methods:
- Literature review of current research and clinical guidelines on CHD prevention and treatment.
- Analysis of controversies surrounding screening criteria and therapeutic interventions.
- Examination of treatment disparities in different demographic groups.
Main Results:
- General agreement exists on treating hypercholesterolemia for secondary CHD prevention.
- Primary prevention is controversial except in diabetic patients due to their elevated CHD risk.
- Postmenopausal women and the elderly are often undertreated, while young adults may be underdiagnosed.
Conclusions:
- Ongoing clinical trials are expected to provide evidence to resolve current controversies in CHD prevention and treatment strategies.
- Personalized approaches to CHD prevention and treatment are needed, considering patient demographics and risk factors.
- Further research is crucial to optimize screening and treatment protocols for all patient populations to reduce CHD morbidity and mortality.
Abstract:
Coronary heart disease (CHD) remains a leading cause of morbidity and mortality in the United States, despite our better understanding of the pathobiology of atherosclerosis, our knowledge of risk factors, the widespread availability of inexpensive cholesterol screening, and the availability of effective and well-tolerated cholesterol-lowering agents. Advances in these areas have created controversies regarding who should be screened and treated for primary or secondary prevention of coronary events. The advent of the statin class of lipid-lowering agents represented a major advance, because they are much more effective and better tolerated than previous agents. There is general agreement that patients with hypercholesterolemia and established CHD require treatment for secondary prevention of recurrent coronary events. Primary prevention is controversial in all patient groups except those with diabetes, because their risk of developing CHD is dramatically increased. Postmenopausal women and the elderly are undertreated, whereas young adults may be underdiagnosed and undertreated. Several ongoing trials may resolve the controversies about which patient groups will benefit from different prevention and treatment strategies.
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care